Panel Discussion: Strengthening Tumor‑Informed MRD Assays with Standardized Analytical Validation to Ensure Reliable Detection & Confident Clinical Interpretation

6:10 pm - Tuesday 6th October 2026

  • What factors define intended use for MRD at predefined post-surgery time points and how to align study designs to qualitative detection endpoints?
  • How to design precision repeatability and reproducibility across instruments, operators and sites under clinical sample scarcity?
  • How can assay accuracy be robustly established when orthogonal reference methods are less sensitive than the MRD assay?

Speakers:

Jon Baden
Executive Director & Head, Precision Medicine
Bristol Myers Squibb
Angela Silvestro
Director, Companion Diagnostics
GSK
Fernando Cruz-Guilloty
Director, Oncology Precision Medicine & Diagnostics
Johnson & Johnson Innovative Medicine
Nancy Krunic, Ph.D
Vice President & Precision Medicine Head, Diagnostic Sciences & Partnerships
Novartis
Lauren Leiman
Executive Director
BLOODPAC